Please login to the form below

Immunomedics

This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried

Latest news

Seattle Genetics claims key US approval for Adcetris

The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’CEO
Activists torpedo Immunomedics deal with Seattle Genetics

Activists torpedo Immunomedics deal with Seattle Genetics. venBio says deal will enrich CEO at shareholders' expense. ... Immunomedics shareholders - pointing out that the company has failed to bring any products to market in its 35-year history.
Move on Immunomedics board puts Seattle Genetics deal in doubt

Move on Immunomedics board puts Seattle Genetics deal in doubt. Four venBio candidates voted to the board which gives group a majority. ... and punishing Immunomedics for failing to bring any products to market in its 35-year history.
Seattle Genetics signs $2bn deal for Immunomedics' cancer drug

Seattle Genetics signs $2bn deal for Immunomedics' cancer drug. Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end. ... Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative
Pacira CEO David Stack joins board of health monitoring firm Medivo

He has also held senior positions at Immunomedics and Roche. “ This is a perfect time for me to reconnect with Sundeep and his management team at Medivo,” Stack said. “

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... The whole episode resulted in the resignation of the Immunomedics CEO and CSO.
Deal Watch March 2017

In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained
Deal Watch February 2017

Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
Pharma deals during October 2013

The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... On termination, all rights revert back to Immunomedics and it is expected that arbitration will continue in parallel with

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Director – Global Healthcare PR: Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Scientific Director: Highly Competitive Salary &Benefits

Director – Head of Public Affairs: Neg

Account Manager, Healthcare Advertising: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Project / Account Manager (Medical Education): Salary TBC

Editorial Director – Medical Education: Neg

Senior Account Director development role to Business Director, H...: Excellent package

Account Director - Digital: Great salary and benefits

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Account Executive – Medical Communications: Salary TBC

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Associate Medical Director: Salary TBC

Scientific Team Lead: Competitive Salary

Account Director: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Director Healthcare PR Communications: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies: With patient numbers set to soar, how can we make a difference?...
Redefining communications excellence: How to be heard in today’s multichannel, multistakeholder, multimedia world...